Eintrag weiter verarbeiten
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from...
Gespeichert in:
| Zeitschriftentitel: | Antimicrobial Agents and Chemotherapy |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Antimicrobial Agents and Chemotherapy, 35, 1991, 3, S. 584-586 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society for Microbiology
|
| Schlagwörter: |
| author_facet |
Jones, R N Goldstein, F W Zhou, X Y Jones, R N Goldstein, F W Zhou, X Y |
|---|---|
| author |
Jones, R N Goldstein, F W Zhou, X Y |
| spellingShingle |
Jones, R N Goldstein, F W Zhou, X Y Antimicrobial Agents and Chemotherapy Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States Infectious Diseases Pharmacology (medical) Pharmacology |
| author_sort |
jones, r n |
| spelling |
Jones, R N Goldstein, F W Zhou, X Y 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.35.3.584 <jats:p>MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2- to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12 micrograms/ml; S. aureus, oxacillin resistant, 0.25 micrograms/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25 micrograms/ml; and CNS, oxacillin resistant, 2 micrograms/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to greater than 128 micrograms/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.</jats:p> Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States Antimicrobial Agents and Chemotherapy |
| doi_str_mv |
10.1128/aac.35.3.584 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMzUuMy41ODQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMzUuMy41ODQ |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society for Microbiology, 1991 |
| imprint_str_mv |
American Society for Microbiology, 1991 |
| issn |
0066-4804 1098-6596 |
| issn_str_mv |
0066-4804 1098-6596 |
| language |
English |
| mega_collection |
American Society for Microbiology (CrossRef) |
| match_str |
jones1991activitiesoftwonewteicoplaninamidederivativesmdl62211andmdl62873comparedwithactivitiesofteicoplaninandvancomycinagainst800recentstaphylococcalisolatesfromfranceandtheunitedstates |
| publishDateSort |
1991 |
| publisher |
American Society for Microbiology |
| recordtype |
ai |
| record_format |
ai |
| series |
Antimicrobial Agents and Chemotherapy |
| source_id |
49 |
| title |
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_unstemmed |
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_full |
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_fullStr |
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_full_unstemmed |
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_short |
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_sort |
activities of two new teicoplanin amide derivatives (mdl 62211 and mdl 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from france and the united states |
| topic |
Infectious Diseases Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1128/aac.35.3.584 |
| publishDate |
1991 |
| physical |
584-586 |
| description |
<jats:p>MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2- to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12 micrograms/ml; S. aureus, oxacillin resistant, 0.25 micrograms/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25 micrograms/ml; and CNS, oxacillin resistant, 2 micrograms/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to greater than 128 micrograms/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.</jats:p> |
| container_issue |
3 |
| container_start_page |
584 |
| container_title |
Antimicrobial Agents and Chemotherapy |
| container_volume |
35 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792322412528795648 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:17:20.327Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Activities+of+two+new+teicoplanin+amide+derivatives+%28MDL+62211+and+MDL+62873%29+compared+with+activities+of+teicoplanin+and+vancomycin+against+800+recent+staphylococcal+isolates+from+France+and+the+United+States&rft.date=1991-03-01&genre=article&issn=1098-6596&volume=35&issue=3&spage=584&epage=586&pages=584-586&jtitle=Antimicrobial+Agents+and+Chemotherapy&atitle=Activities+of+two+new+teicoplanin+amide+derivatives+%28MDL+62211+and+MDL+62873%29+compared+with+activities+of+teicoplanin+and+vancomycin+against+800+recent+staphylococcal+isolates+from+France+and+the+United+States&aulast=Zhou&aufirst=X+Y&rft_id=info%3Adoi%2F10.1128%2Faac.35.3.584&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792322412528795648 |
| author | Jones, R N, Goldstein, F W, Zhou, X Y |
| author_facet | Jones, R N, Goldstein, F W, Zhou, X Y, Jones, R N, Goldstein, F W, Zhou, X Y |
| author_sort | jones, r n |
| container_issue | 3 |
| container_start_page | 584 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 35 |
| description | <jats:p>MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2- to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12 micrograms/ml; S. aureus, oxacillin resistant, 0.25 micrograms/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25 micrograms/ml; and CNS, oxacillin resistant, 2 micrograms/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to greater than 128 micrograms/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.</jats:p> |
| doi_str_mv | 10.1128/aac.35.3.584 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMzUuMy41ODQ |
| imprint | American Society for Microbiology, 1991 |
| imprint_str_mv | American Society for Microbiology, 1991 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0066-4804, 1098-6596 |
| issn_str_mv | 0066-4804, 1098-6596 |
| language | English |
| last_indexed | 2024-03-01T11:17:20.327Z |
| match_str | jones1991activitiesoftwonewteicoplaninamidederivativesmdl62211andmdl62873comparedwithactivitiesofteicoplaninandvancomycinagainst800recentstaphylococcalisolatesfromfranceandtheunitedstates |
| mega_collection | American Society for Microbiology (CrossRef) |
| physical | 584-586 |
| publishDate | 1991 |
| publishDateSort | 1991 |
| publisher | American Society for Microbiology |
| record_format | ai |
| recordtype | ai |
| series | Antimicrobial Agents and Chemotherapy |
| source_id | 49 |
| spelling | Jones, R N Goldstein, F W Zhou, X Y 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.35.3.584 <jats:p>MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2- to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12 micrograms/ml; S. aureus, oxacillin resistant, 0.25 micrograms/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25 micrograms/ml; and CNS, oxacillin resistant, 2 micrograms/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to greater than 128 micrograms/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.</jats:p> Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States Antimicrobial Agents and Chemotherapy |
| spellingShingle | Jones, R N, Goldstein, F W, Zhou, X Y, Antimicrobial Agents and Chemotherapy, Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States, Infectious Diseases, Pharmacology (medical), Pharmacology |
| title | Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_full | Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_fullStr | Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_full_unstemmed | Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_short | Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| title_sort | activities of two new teicoplanin amide derivatives (mdl 62211 and mdl 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from france and the united states |
| title_unstemmed | Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States |
| topic | Infectious Diseases, Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1128/aac.35.3.584 |